Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
AssigneeVerimmune Inc.
InventorsJoshua Weiyuan WANG, Nattha INGAVAT
Life of this patent
Estimating the term…
Abstract
This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.
Claims20
A virus-like particle (VLP), comprising in order from amino terminus to carboxy terminus:
- a) a papilloma virus L1 protein,
- b) at least one antigen conjugated to the L1 protein, wherein the at least one antigen comprises at least one T cell epitope, and
- c) at least one peptide cleavage sequence,
- wherein the T cell epitope is from a human pathogen heterologous to the papilloma virus of the VLP, and
- wherein the at least one antigen is not a tumor-associated antigen.
A method of inhibiting tumor growth, tumor progression, or tumor metastasis in a subject in need thereof, which comprises contacting a tumor cell or cancer cell with an effective amount of a virus-like particle (VLP) composition,
- wherein the VLP comprises in order from amino terminus to carboxy terminus:
- a) a papilloma virus L1 protein,
- b) at least one antigen conjugated to the L1 protein, wherein the at least one antigen comprises at least one T cell epitope, and
- c) at least one peptide cleavage sequence,
- wherein the T cell epitope is from a human pathogen heterologous to the papilloma virus of the VLP, and
- wherein the at least one antigen is not a tumor-associated antigen.
Dependencies are inferred from the claim text.